Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis.
Iwamoto N, Fukui S, Umeda M, Nishino A, Nakashima Y, Suzuki T, Horai Y, Nonaka F, Okada A, Koga T, Kawashiri SY, Fujikawa K, Aramaki T, Ichinose K, Hirai Y, Tamai M, Nakamura H, Terada K, Nakashima M, Mizokami A, Origuchi T, Eguchi K, Ueki Y, Kawakami A.
Iwamoto N, et al. Among authors: hirai y.
Mod Rheumatol. 2016 Sep;26(5):662-6. doi: 10.3109/14397595.2015.1129692. Epub 2016 Feb 16.
Mod Rheumatol. 2016.
PMID: 26708444